Back to profile Contact person for... - PJ (Paul) Wichgers Schreur MSc type_page Antigen discovery and presentation Wageningen Bioveterinary Research (WBVR) is involved in vaccine development projects for specific pathogens in close collaboration with public and... Rift Valley fever Rift Valley fever (RVF) is a viral zoonosis that primarily affects animals but also has the capacity to infect humans. Wageningen Bioveterinary... Crimean Congo haemorrhagic fever Crimean Congo haemorrhagic fever virus (CCHFV) is a bunya virus transmitted from animals to humans via ticks. In humans, the virus can cause serious... News Novel Rift Valley fever vaccine dosed in Phase I human trial 18 augustus 2022 | The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA... New vaccine against Rift Valley fever is safe and effective in pregnant sheep 27 januari 2021 | A study by Wageningen Bioveterinary Research (WBVR), in collaboration with BunyaVax and Ceva Animal Health, shows that a new live-attenuated candidate... Synthetic antibodies built with bacterial superglue could help fight emerging viruses 29 april 2020 | Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in... How to make a corona vaccine 4 februari 2020 | Scientists around the globe are seeking a vaccine for the coronavirus (SARS-CoV-2) that causes the disease COVID-19. Virologist and vaccine developer... CEPI awards contract worth up to US$12.5 million to develop a human vaccine against Rift Valley fever 10 juli 2019 | Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI)... 123Next